Duration of Protection Provided by Live Attenuated Influenza Vaccine in Children

BACKGROUND:Reliable availability of influenza vaccine before October could enable the vaccination of many children who might not otherwise be vaccinated. METHODS:Available data for children were analyzed to describe protection provided by live attenuated influenza vaccine (LAIV) for greater than 5 m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Pediatric infectious disease journal 2008-08, Vol.27 (8), p.744-748
Hauptverfasser: Ambrose, Christopher S, Yi, Tingting, Walker, Robert E, Connor, Edward M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND:Reliable availability of influenza vaccine before October could enable the vaccination of many children who might not otherwise be vaccinated. METHODS:Available data for children were analyzed to describe protection provided by live attenuated influenza vaccine (LAIV) for greater than 5 months postvaccination. RESULTS:Four studies conducted in children aged 6 months to 18 years were identified. Culture-confirmed efficacy against A/H1N1 and A/H3N2 strains at 9–12 months postvaccination was 77% [95% confidence interval (CI)53–89%] to 100% (95% CI68–100%) and through a second influenza season without revaccination was 56% (95% CI31–73%) and 57% (95% CI6–82%), respectively. Against B strains, 1 study demonstrated 86% (95% CI59–95%) efficacy at 5–7 months. Another study demonstrated 27% (95% CI−62% to 67%) efficacy at 9–12 months compared with 74% (95% CI39–89%) at 1 to
ISSN:0891-3668
1532-0987
DOI:10.1097/INF.0b013e318174e0f8